The treatment options for advanced ERα + (HER2-) breast cancer commonly include endocrine therapies, such as aromatase inhibitors or selective estrogen receptor degraders/ modulators (SERDs and SERMs), administered either alone or in combination with targeted therapies like cyclin-dependent kinase inhibitors or mTOR inhibitors4. Here, ESR1 is linked to breast carcinoma.